Ditchcarbon
  • Contact
  1. Organizations
  2. Swedish Orphan Biovitrum
Public Profile
Pharmaceutical Preparation Manufacturing
SE
updated a month ago

Swedish Orphan Biovitrum

Company website

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a leading biopharmaceutical company headquartered in Sweden (SE). Founded in 1991, Sobi has established itself as a key player in the biotechnology industry, focusing on rare diseases and specialty care. With a strong operational presence across Europe, North America, and the Asia-Pacific region, Sobi is dedicated to developing innovative therapies that address unmet medical needs. Sobi's core product portfolio includes treatments for haemophilia, inflammation, and genetic disorders, distinguished by their commitment to patient-centric solutions and advanced biopharmaceutical technologies. The company has achieved significant milestones, including strategic partnerships and a robust pipeline of therapies, solidifying its market position as a trusted provider in the rare disease sector. Sobi continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by complex health conditions.

DitchCarbon Score

How does Swedish Orphan Biovitrum's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

56

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

32

Industry Benchmark

Swedish Orphan Biovitrum's score of 56 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.

73%

Let us know if this data was useful to you

Swedish Orphan Biovitrum's reported carbon emissions

In 2024, Swedish Orphan Biovitrum (Sobi) reported total carbon emissions of approximately 253,324,000 kg CO2e. This includes 1,097,000 kg CO2e from Scope 1 emissions, which primarily stem from mobile combustion (1,048,000 kg CO2e) and stationary combustion (33,000 kg CO2e). Scope 2 emissions totalled about 771,000 kg CO2e, with purchased electricity contributing 539,000 kg CO2e. The most significant portion of emissions came from Scope 3, amounting to approximately 251,456,000 kg CO2e, largely driven by purchased goods and services (216,133,000 kg CO2e). Sobi has set ambitious climate commitments, aiming for a 37.8% absolute reduction in combined Scope 1 and 2 emissions by 2029, using 2023 as the base year. Additionally, the company is committed to achieving net zero emissions for both Scope 1 and Scope 2 by 2030. This commitment includes a target to ensure that 65% of its suppliers, by spend, will have science-based targets by FY2029. In 2023, Sobi's total emissions were approximately 194,977,000 kg CO2e, indicating a significant increase in emissions from the previous year, which reported about 114,282,000 kg CO2e in 2022. The company is actively working towards reducing its operational greenhouse gas footprint, with a specific focus on both immediate and long-term sustainability goals.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20172018201920202021202220232024
Scope 1
156,000
000,000
000,000
000,000
000,000
000,000
0,000,000
0,000,000
Scope 2
129,000
000,000
00,000
0,000,000
000,000
000,000
000,000
000,000
Scope 3
922,000
0,000,000
0,000,000
-
-
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Swedish Orphan Biovitrum's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Swedish Orphan Biovitrum is in SE, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Swedish Orphan Biovitrum is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

UNO's

US
•
Pharmaceutical Preparation Manufacturing
Updated 25 days ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated about 5 hours ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Biogen

US
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251009.1
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy